Revolution Medicines has a pill called daraxonrasib. You take it daily. It blocks something called KRAS, which until recently was considered undruggable, like my landlord.
In a Phase 3 trial of 500 patients, it pushed survival from 6.7 months to 13.2. A 60% reduction in risk of death. Genuinely impressive. I won't be around for the ten-year follow-up, but good for them.
The catch: 86% get a skin rash. So you spend the bonus half-year itchy, trying to remember whether your Netflix password has a capital N.
Quality of life improved. Pain went down. Patients stayed on treatment longer. The FDA is reviewing it.
Thirteen months. Long enough to write a will. Short enough to skip the dentist.
Based on the original article "A Breakthrough Drug Just Achieved The 'Impossible' For Pancreatic Cancer".
